WWW.DISSERS.RU


...
    !

Pages:     | 1 | 2 ||

23. Duffy M. J., Duggan c. The urokinase plasminogen 3. PaX8-Peroxisome Proliferator-activated Receptor activator system: a rich source of tumour markers for the {gamma} (PPaR {gamma}) Dis-rupts Normal PaX8 or PPaR individualized management of patients with cancer // clin.

{gamma} Transcriptional Function and Stimulates Follicular Biochem. 2004. Vol. 37. P. 541 548.

Thyroid cell growth / a. y. au, c. McBride, K. g. wilhelm [et al.] // 24. Kushlinskij N. e. Klinicheskaja rol sistemy aktivacii endocrinology. 2006. Vol. 147. P. 367 376.

plazminogena v opuho-ljah cheloveka // Molekuljarnaja medicina.

4. a preoperative diagnostic test that distinguishes benign 2007. 1. S. 4 8.

from malignant thyroid carci-noma based on gene expression / 25. The angiotensin I-converting enzyme gene J. M. cerutti, R. Delcelo, M. J. amadei [et al.] // J. clin. In-vest.

insertion/deletion polymorphism is linked to early gastric cancer / 2004. Vol. 113. P. 1234 1242.

M. P. ebert, u. Lendeckel, S. westphal [et al.] // cancer epidemiol.

5. Riesco-eizaquirre g., Santisteban P. Molecular biology of Biomarkers Prev. 2005. Vol. 14, 12. P. 2987 1989.

thyroid cancer initiation // clin. Transl. Oncol. 2007. Vol. 9, 11.

26. Rocken c., Lendeckel u., Dierkes J., westphal S. The P. 686 693.

number of lymph node metas-tases in gastric cancer correlates 6. Molecular classification of papillary thyroid carcinoma:

with the angiotensin I-converting enzyme gene inser-tion/deletion distinct BRaF, RaS, and ReT/PTc mutation-specific gene polymorphism // clin. cancer Res. 2005. Vol. 1, 11.

expression profiles discovered by DNa microarray analysis / P. 2526 2530.

T. J. giordano, R. Kuick, D. g. Thomas [et al.] // Oncogene. 2005.

27. angiotensin-converting enzyme gene insertion/deletion Vol. 24. P. 6646 6654.

polymorphism and breast can-cer risk // cancer epidemiol.

7. The ReT/PTc-RaS-BRaF linear signaling cascade Biomarkers Prev. 2005. Vol. 14, 9. P. 2143 2146.

mediates the motile and mitogenic phenotype of thyroid cancer 28. Koh J. T., Biggins J. B. Ligand-receptor engineering cells / R. M. Melillo, M. D. castellone, V. guarino [et al.] // J. clin.

and its application towards the complementation of genetic Invest. 2005. Vol. 115. P. 1068 1081.

disease and target identification / a. M. gonzalez-Zuloeta Ladd, 8. Molecular pathology of well-differentiated thyroid a. a. Vasquez, F. a. Sayed-Tabatabaei [et al.] // curr. Top. Med.

carcinomas / M. Sobrinho-Simoes, a. Preto, a. S. Rocha [et al.] // chem. 2005. Vol. 5, 4. P. 413 420.

Virchows arch. 2005. Vol. 447. P. 787 793.

29. angiotensin I-converting enzyme gene insertion/deletion 9. Prognostic factors in papillary thyroid cancer: an evaluation polymorphism and endome-trial human cancer in normotensive of 601 consecutive pa-tients / P. Siironen, J. Louhimo, S. Nordling and hypertensive women / M. Freitas-Silva, D. Pereira, c. coelho [et al.] // Tumour Biol. 2005. Vol. 26, 2. P. 57 64.

[et al.] // cancer gene cytogenet. 2004. Vol. 155, 1. P. 42 46.

10. Biological activity of activating thyroid-stimulating 30. chang H. S., Nam K. H., chung w. y., Park c. S. anaplastic hormone receptor mutants depends on the cellular context / thyroid carcinoma: a the-rapeutic dilemma // yonsei Med. J. 2005.

D. Fuhrer, M. D. Lewis, F. alkhafaji [et al.] // endocrinology. 2003.

Vol. 46, 6. P. 759 764.

Vol. 144. P. 4018 4030.

31. angiotensin-converting enzyme gene insertion/deletion 11. Specific haplotypes of the ReT proto-oncogene are overpolymorphism is associated with risk of oral precancerous lesion represented in patients with sporadic papillary thyroid carcinoma in betel quid chewers / F. M. chung, y. H. yang, c. H. chen [et al.] / F. Lesueur, M. McKay, J. D. corbex [et al.] // J. Med. genet.

// Br. J. cancer. 2005. Vol. 93, 5. P. 602 606.

2002. Vol. 39, 4. P. 260 2655.

32. Martin M. D., Matrisian L. M. The other side of MMPs:

12. ReT/PTc and cK19 expression in papillary thyroid protective roles in tumor pro-gression // cancer Metastasis Rev.

carcinoma and its clinicopatho-logic correlation / w. y. chung, 2007. Vol. 26, 3 4. P. 717 724.

e. Shin, w. I. yang [et al.] // J. Korean Med. Sci. 2005. Vol. 20, 33. Invasiveness of cutaneous malignant melanoma is 1. P. 98 104.

influenced by matrix metalloprotei-nase 1 gene polymorphism / 13. High prevalence of BRaF mutations in thyroid cancer:

genetic evidence for constitu-tive activation of the ReT/PTc- S. ye, S. Dhillon, S. J. Turner [et al.] // cancer Res. 2001. Vol. 15, 4. P. 1296 1298.

RaSBRaF signaling pathway in papillary thyroid carcinoma / 34. Pepper M. S. Lymphangiogenesis and tumor metastasis:

e. T. Kimura, M. N. Nikiforova, Z. Zhu [et al.] // cancer Res. 2003.

more questions than answers // Lymphology. 2000. Vol. 33, 4.

Vol. 63. P. 1454 1457.

P. 144 147.

14. BRaF (V599e) mutation is the leading genetic event 35. Johansson N., ahonen M. Matrix metalloproteinases in in adult sporadic papillary thy-roid carcinomas / e. Puxeddu, tumor invasion // cell. Mol. Life Sci. 2000. Vol. 20, 1. P. 5 15.

S. Moretti, R. elisei [et al.] // J. clin. endocrinol. Metab. 2004.

36. a single Nucleotide Polymorphism in the MMP-3 promoter Vol. 89, 5. P. 2414 2420.

enhances breast cancer susceptibility / g. ghilardi, M. L. Biondi, 15. BRaF mutations are associated with some histologica l types of papillary thyroid car-cinoma / V. Trovisco, I. Vieira M. caputo [et al.] // cancer Res. 2002. Vol. 8. P. 3820 3823.

de castro, P. Soares [et al.] // J. Pathol. 2004. Vol. 202, 2. 37. Bogusiewicz M., Stryjecka-Zimmer M., P. 247 251. Szymanski M. activity of matrix metallopro-teinases-2 and 16. Proximity of chromosomal loci that participate in radiation- in advanced laryngeal cancer // Otolaryngol. Head Neck. Surg.

induced rearrangements in human cells / M. N. Nikiforova, 2003. Vol. 128, 1. P. 132 136.

J. R. Stringer, R. Blough [et al.] // Science. 2000. Vol. 290. 38. Shiomi T., Okada y. MMP-1 and MMP-7 in invasion and P. 138 141. metastasis of human cancers // cancer Metastasis Rev. 2003.

17. Proline homozygosity in codon 72 of p53 is a factor of Vol. 22. P. 145 152.

susceptibility for thyroid cancer / F. granja, J. Morari, e. c. Morari 39. Reichenberger F., eickelberg O., wyser c., [et al.] // cancer Lett. 2004. Vol. 16, 210. P. 151 157. Perruchoud a. P. Distinct endobronchial expression of matrix18. gST profiling may be useful in the screening for thyroid metalloproteinases (MMP) and their endogenous inhibitors in lung nodule malignancy / F. gran-ja, J. Morari, e. c. Morari [et al.] // cancer // Swiss Med. wkly. 2001. Vol. 19, 131. P. 273 279.

cancer Lett. 2004. Vol. 25, 209. P. 129 137. 40. Bogatikov a. a. Prognosticheskoe znachenie kliniko19. Shi y. B, Fu L, Hasebe T., Ishizuya-Oka a. Regulation of geneticheskih faktorov v hirurgicheskom lechenii papilljarnogo extracellular matrix remode-ling and cell fate determination by raka witovidnoj zhelezy: avtoref. dis. kand. med. nauk. SPb., matrix metalloproteinase stromelysin-3 during thyroid hormone- 2010. 27 s.

- . 2012. . 8, 3.

Pages:     | 1 | 2 ||



2011 www.dissers.ru -

, .
, , , , 1-2 .